Abstract：
OBJECTIVE: To define the indications for each imaging modality in the screening, characterization, extension and follow-up of salivary gland tumors.
METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: If a swelling of a salivary gland is palpable for 3 weeks, an ultrasound scan is recommended to confirm a tumoral lesion and rule out differential diagnoses. For a salivary gland tumor, MRI is recommended with diffusion-weighted and dynamic contrast-enhanced techniques. In the case of histologically proven malignancy or a highly suspicious lesion, a CT scan of the neck and chest is recommended to assess the tumor, lymph nodes and metastases. FDG-PET is not currently recommended in routine clinical practice for initial diagnosis, assessment of extension, evaluation of response to treatment, staging of recurrence, or follow-up of salivary gland tumors.
CONCLUSIONS: Assessing salivary tumors is based on MRI. Extension assessment is based on neck and chest CT.
METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group who drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: If a swelling of a salivary gland is palpable for 3 weeks, an ultrasound scan is recommended to confirm a tumoral lesion and rule out differential diagnoses. For a salivary gland tumor, MRI is recommended with diffusion-weighted and dynamic contrast-enhanced techniques. In the case of histologically proven malignancy or a highly suspicious lesion, a CT scan of the neck and chest is recommended to assess the tumor, lymph nodes and metastases. FDG-PET is not currently recommended in routine clinical practice for initial diagnosis, assessment of extension, evaluation of response to treatment, staging of recurrence, or follow-up of salivary gland tumors.
CONCLUSIONS: Assessing salivary tumors is based on MRI. Extension assessment is based on neck and chest CT.
摘要：
目的：确定筛查中每种成像模式的适应症，表征，涎腺肿瘤的延伸和随访。
方法：法国罕见头颈部肿瘤网络（REFCOR）成立了一个指导小组，该小组对Medline上发表的文献进行了叙述性综述，并提出了建议。然后由评级小组评估对建议的遵守程度，根据正式共识方法。
结果：如果唾液腺肿胀可触及3周，建议进行超声扫描以确认肿瘤病变并排除鉴别诊断。对于唾液腺肿瘤，建议使用扩散加权和动态对比增强技术进行MRI。在组织学证实的恶性肿瘤或高度可疑病变的情况下，建议对颈部和胸部进行CT扫描以评估肿瘤，淋巴结和转移。FDG-PET目前在常规临床实践中不推荐用于初始诊断，扩展评估，对治疗反应的评估，复发分期,或唾液腺肿瘤的随访。
结论：评估涎腺肿瘤是基于MRI。扩展评估基于颈部和胸部CT。
方法：法国罕见头颈部肿瘤网络（REFCOR）成立了一个指导小组，该小组对Medline上发表的文献进行了叙述性综述，并提出了建议。然后由评级小组评估对建议的遵守程度，根据正式共识方法。
结果：如果唾液腺肿胀可触及3周，建议进行超声扫描以确认肿瘤病变并排除鉴别诊断。对于唾液腺肿瘤，建议使用扩散加权和动态对比增强技术进行MRI。在组织学证实的恶性肿瘤或高度可疑病变的情况下，建议对颈部和胸部进行CT扫描以评估肿瘤，淋巴结和转移。FDG-PET目前在常规临床实践中不推荐用于初始诊断，扩展评估，对治疗反应的评估，复发分期,或唾液腺肿瘤的随访。
结论：评估涎腺肿瘤是基于MRI。扩展评估基于颈部和胸部CT。
